Guggenheim Capital LLC cut its stake in SurModics, Inc. (NASDAQ:SRDX) by 36.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,775 shares of the company’s stock after selling 17,393 shares during the period. Guggenheim Capital LLC owned approximately 0.22% of SurModics worth $756,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capstone Asset Management Co. raised its position in shares of SurModics by 1.6% in the third quarter. Capstone Asset Management Co. now owns 8,780 shares of the company’s stock valued at $264,000 after buying an additional 140 shares during the last quarter. New York State Teachers Retirement System raised its position in shares of SurModics by 0.6% in the fourth quarter. New York State Teachers Retirement System now owns 47,962 shares of the company’s stock valued at $1,218,000 after buying an additional 300 shares during the last quarter. First Quadrant L P CA raised its position in shares of SurModics by 9.4% in the third quarter. First Quadrant L P CA now owns 4,374 shares of the company’s stock valued at $132,000 after buying an additional 374 shares during the last quarter. Comerica Bank raised its position in shares of SurModics by 5.2% in the fourth quarter. Comerica Bank now owns 13,874 shares of the company’s stock valued at $345,000 after buying an additional 691 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of SurModics by 0.9% in the third quarter. Bank of New York Mellon Corp now owns 185,601 shares of the company’s stock valued at $5,585,000 after buying an additional 1,632 shares during the last quarter. Institutional investors and hedge funds own 85.59% of the company’s stock.
SurModics, Inc. (NASDAQ:SRDX) opened at 24.45 on Friday. SurModics, Inc. has a one year low of $19.86 and a one year high of $30.75. The firm has a 50-day moving average price of $23.91 and a 200 day moving average price of $25.24. The company has a market cap of $324.35 million, a price-to-earnings ratio of 33.49 and a beta of 1.03.
SurModics (NASDAQ:SRDX) last released its quarterly earnings data on Thursday, February 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.10. The business had revenue of $17.80 million for the quarter, compared to analysts’ expectations of $15.81 million. SurModics had a return on equity of 13.14% and a net margin of 13.46%. The firm’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 EPS. Equities analysts expect that SurModics, Inc. will post $0.32 earnings per share for the current fiscal year.
Separately, Zacks Investment Research lowered SurModics from a “hold” rating to a “sell” rating in a report on Monday, February 6th.
SurModics Company Profile
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.